Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
63
Participants
Timeline
Start Date
April 1, 2024
Primary Completion Date
November 30, 2025
Study Completion Date
September 30, 2026
Conditions
Colorectal Cancer
Interventions
DRUG
Liposomal irinotecan
70 mg/m² IV
DRUG
Capecitabine
1000 mg/m² PO BID
DRUG
Bevacizumab
5mg/kg IV
All Listed Sponsors
lead
Harbin Medical University
OTHER
NCT06192680 - Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter